Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB) Accumulated Expenses (2023 - 2025)

Nuvation Bio (NUVB) has disclosed Accumulated Expenses for 3 consecutive years, with $45.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Expenses rose 37.61% to $45.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $45.2 million, a 37.61% increase, with the full-year FY2025 number at $45.2 million, up 37.61% from a year prior.
  • Accumulated Expenses was $45.2 million for Q4 2025 at Nuvation Bio, up from $32.6 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $45.2 million in Q4 2025 to a low of $8.4 million in Q1 2023.
  • A 3-year average of $21.1 million and a median of $21.7 million in 2024 define the central range for Accumulated Expenses.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 235.27% in 2024, then increased 20.15% in 2025.
  • Nuvation Bio's Accumulated Expenses stood at $9.8 million in 2023, then surged by 235.27% to $32.8 million in 2024, then surged by 37.61% to $45.2 million in 2025.
  • Per Business Quant, the three most recent readings for NUVB's Accumulated Expenses are $45.2 million (Q4 2025), $32.6 million (Q3 2025), and $24.0 million (Q2 2025).